1. Search Result

Search Result

Results for "productlist/Q" in MCE Product Catalog:

33

Inhibitors & Agonists

3

Natural
Products

Cat. No. Product Name Target Research Area
  • HY-10388A
    TTA-Q6(isomer)

    Others Others
    TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective T-type Ca 2+ channel antagonist.
  • HY-P1275
    Tertiapin-Q

    Potassium Channel Cardiovascular Disease
    Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir1.1).
  • HY-N7099
    Cue-lure

    Q-lure

    Others Others
    Cue-lure (Q-lure) is a melon fly attractant.
  • HY-101040
    Q203

    IAP6; Telacebec

    Bacterial Infection
    Q203 (IAP6) is a midazopyridine amide compound. Q203 is active against Mycobacterium tuberculosis H37Rv with an MIC50 of 2.7 nM in culture broth medium.
  • HY-16764
    Avarofloxacin

    JNJ-Q2

    Bacterial Infection Inflammation/Immunology
    Avarofloxacin (JNJ-Q2) is a broad-spectrum fluoroquinolone antibacterial drug being developed for the treatment of acute bacterial skin and skin-structure infections and community-acquired pneumonia. Avarofloxacin (JNJ-Q2) is an aminoethylidenylpiperidine fluoroquinolone that demonstrates antibacterial effect against numerous Gram-positive bacteria with a mean 0.12 mg/L MIC90 value. Avarofloxacin (JNJ-Q2) has potential for treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections.
  • HY-10388
    TTA-Q6

    Calcium Channel Neurological Disease
    TTA-Q6 is a selective T-type Ca 2+ channel antagonist, used in the neurological disease.
  • HY-101415
    Coenzyme Q9

    Ubiquinone Q9; CoQ9; Ubiquinone 9

    Endogenous Metabolite Cardiovascular Disease
    Coenzyme Q9, a nine isoprenyl group-containing member of the ubiquinone family, is a normal constituent of human plasma.
  • HY-N0111
    Coenzyme Q10

    CoQ10; Ubiquinone-10

    Ferroptosis Endogenous Metabolite Reactive Oxygen Species Cancer Metabolic Disease Inflammation/Immunology Neurological Disease
    Coenzyme Q10 is an essential cofactor of the electron transport chain and a potent antioxidant agent.
  • HY-12305A
    (R)-Q-VD-OPh

    (R)-QVD-OPH; (R)-Quinoline-Val-Asp-Difluorophenoxymethylketone

    Others Others
    (R)-Q-VD-OPh ((R)-QVD-OPH) is the less active enantiomer of Q-VD-OPha. Q-VD-OPha is an irreversible pan-caspase inhibitor with potent antiapoptotic properties.
  • HY-12305
    Q-VD-OPh

    QVD-OPH; Quinoline-Val-Asp-Difluorophenoxymethylketone

    Caspase Cancer
    Q-VD-OPh is an irreversible pan-caspase inhibitor with potent antiapoptotic properties; inhibits caspase 7 with an IC50 of 48 nM and 25-400 nM for other caspases including caspase 1, 3, 8, 9, 10, and 12. Q-VD-OPh is able to cross the blood-brain barrier.
  • HY-108587
    ICA 110381

    Potassium Channel Neurological Disease
    ICA 110381 (Compound 16) is a KCNQ2/Q3 potassium channel opener for the treatment of epilepsy. ICA 110381 is a KCNQ2/Q3 agonist (EC50=0.38 μM) as well as KCNQ1 antagonist (IC50=15 μM).
  • HY-101396
    ICA-069673

    Potassium Channel Neurological Disease
    ICA-069673 is a KCNQ2/Q3 potassium channel activator with an IC50 of 0.69 μM.
  • HY-113449
    Ubiquinone-1

    Endogenous Metabolite Others
    Ubiquinone-1 is an intermediate in the synthesis of Coenzyme Q.
  • HY-122114
    ICA-27243

    Potassium Channel Neurological Disease
    ICA-27243 is a selective, potent and orally active KCNQ2/Q3 potassium channel opener with an EC50 of 0.38 μM. ICA-27243 is less effective at activating KCNQ4 and KCNQ3/Q5. ICA-27243 has antiepileptic and anticonvulsant effects.
  • HY-12498
    GV-58

    Calcium Channel Neurological Disease
    GV-58 is a potent, selective N- and P/Q-type Ca2+ channels agonist with EC50 of 7.21/8.81 uM for N-type/P-Q-type Ca2+ channel; 20-fold less potent CDK inhibitor activity.
  • HY-114193
    CCR1 antagonist 6

    CCR Inflammation/Immunology Endocrinology
    CCR1 antagonist 6 (compound 16q) is a chemokine receptor 1 (CCR1) antagonist, with an IC50 of 3 nM.
  • HY-A0241
    Dalfopristin

    RP54476

    Bacterial Infection
    Dalfopristin is a semi-synthetic streptogramin antibiotic. Quinupristin/Dalfopristin (Q/D) is a valuable alternative antibiotic to vancomycin for the treatment of multi-drug resistant Enterococcus faecium infections.
  • HY-15811
    XMD8-87

    ACK1-B19

    Tyrosinase Cancer
    XMD8-87 is a potent TNK2 inhibitor with IC50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.
  • HY-N0303
    Idebenone

    Ferroptosis Neurological Disease
    Idebenone is a synthetic variant of coenzyme Q10 (CoQ10), which initially developed for the treatment of Alzheimer's disease and other cognitive defects.
  • HY-101243
    XMD16-5

    Tyrosinase Cancer
    XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively.
  • HY-18690
    Enasidenib

    AG-221

    Isocitrate Dehydrogenase (IDH) Cancer
    Enasidenib is an oral, potent, reversible, selective inhibitor of the IDH2 mutant enzymes, with IC50s of 100 and 400 nM against IDH2 R140Q and IDH2 R172K, respectively.
  • HY-15164A
    Icotinib

    BPI-2009

    EGFR Cancer
    Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFR L858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q.
  • HY-15164
    Icotinib Hydrochloride

    BPI-2009H

    EGFR Cancer
    Icotinib Hydrochloride (BPI-2009) is a potent and specific EGFR inhibitor with an IC50 of 5 nM; also inhibits mutant EGFR L858R, EGFR L858R/T790M, EGFR T790M and EGFR L861Q.
  • HY-15734
    AGI-6780

    Isocitrate Dehydrogenase (IDH) Cancer
    AGI-6780 that potently and selectively inhibits the tumor-associated mutant IDH2 R140Q with IC50 of 23±1.7 nM. AGI-6780 is less potent against IDH2 WT with IC50 of 190±8.1 nM.
  • HY-19702
    PKR-IN-2

    Others Cancer
    PKR-IN-2 is a pyruvate kinase (PKR) activator, extracted from patent WO2014139144A1, compound 160, has an IC50 of <100 nM for. PKR (R510Q), PKR (R532W), PKR (WT), and PKR (WT Cell Based).
  • HY-12755
    ML141

    CID-2950007

    Apoptosis Ras Cancer
    ML141 (CID-2950007) is a potent, allosteric,selective and reversible non-competitive inhibitor of Cdc42 GTPase. ML141 inhibits Cdc42 wild type and Cdc42 Q61L mutant with EC50s of 2.1 and 2.6 μM, respectively. ML141 shows low micromolar potency and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7). ML141 do not show cytotoxicity in multiple cell lines.
  • HY-13011A
    Alectinib Hydrochloride

    CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride

    ALK Cancer
    Alectinib Hydrochloride (CH5424802 Hydrochloride; RO5424802 Hydrochloride; AF-802 Hydrochloride) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-B1720
    Ubiquinol

    Ubiquinol-10; CoQH2-10

    Endogenous Metabolite Others
    Ubiquinol (Ubiquinol-10) is a reduced form of coenzyme Q10 (CoQ10). Ubiquinol is a potent antioxidant that has the capacity to protect Vitamin E, and also helps to regenerate depleted vitamin E and Vitamin C. Ubiquinol is both lipophilic and hydrophilic and acts as transmembrane factor preventing lipid peroxidation and propagation by transferring electrons to ROS.
  • HY-B0793
    AZ-5104

    EGFR Cancer
    AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an EGFR inhibitor with IC50s of 1, 6, 1, 25 and 7 nM for EGFR L858R/T790M, EGFR L858R, EGFR L861Q, EGFR and ErbB4, respectively.
  • HY-13011
    Alectinib

    CH5424802; RO5424802; AF802

    ALK Cancer
    Alectinib (CH5424802; RO5424802; AF802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
  • HY-13238A
    Dolutegravir sodium

    S/GSK1349572 sodium

    HIV Integrase HIV Infection
    Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).
  • HY-104042
    Vorasidenib

    AG-881

    Isocitrate Dehydrogenase (IDH) Cancer
    Vorasidenib (AG-881) is an orally available, brain penetrant second-generation dual mutant isocitrate dehydrogenases 1 and 2 (mIDH1/2) inhibitor. Vorasidenib (AG-881) exhibits nanomolar inhibition of (D)-2-hydroxyglutarate (D-2-HG), and the IC50 ranges of 0.04~22 nM against IDH1 R132C, IDH1 R132G, IDH1 R132H and IDH1 R132S and 7~14 nM against IDH2 R140Q and 130 nM against IDH2 R172K.
  • HY-13238
    Dolutegravir

    S/GSK1349572

    HIV Integrase HIV Infection
    Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50=3.6-5.8 nM).